Cyclosporine A (CsA) is a complex lypophylic drug known to bind mainly to red cells and it’s cell target the lymphocyte (Lc). This study was undertaken to determine the effect of several parameters such as hematocrit (Hct), CsA whole blood maximum concentration (Cmax), induction therapy and body mass index (BMI) on CsA Lc maximum levels (LTmL) in stable de novo kidney transplant patients. Thirty three (33) patients with stable graft function were included in the study. Seventeen (17) received anti-IL2R (IL2) and 16 Anti Thymocyte Globulin (ATG). CsA LTmL were determined on a monthly basis for 6 months post-transplant and analyzed in relation to Hct, Cmax, BMI and the type of induction therapy. CsA LTmL inversely correlated with both Hct (R:-0.90) and BMI (R: -0.98) in a linear fashion. In contrast, no relationship was observed with either CsA Cmax (R: 0.05) or dose (R: 0.09). ATG patients had significantly higher means of CsA LTmL over the first 4 months post-transplant when compared to their IL2 counterparts (176, 115, 87, 80, Vs 60, 60, 47, 37 pg/Lc) with p< 0.001, p< 0.001, p< 0.002 and p< 0.04 respectively despite lower Cmax in the ATG group. This was paralleled by a significantly lower Hct (p<0.01), BMI (p<0.01) and Lc count (p<0.01) in the ATG group in comparison to the IL2 one. Serum creatinine levels and CsA doses were comparable in both groups over the study period. These results suggest that high Hct and BMI adversely affect CsA Lc binding which seems to be unrelated to Cmax. ATG treated patients have higher CsA LTmL than those on IL2 given the Lc lowering effect of ATG during the early post-transplant period. These parameters should be accounted for in CsA LTmL monitored kidney transplant patients.